Medical Advantages os magic mushrooms.
Following a groundbreaking study in 2016, researchers at NYU Grossman School of Medicine found that a single treatment with a single dose of psilocybin, a compound contained in psychedelic mushrooms, combined with psychotherapy, was emotional and We have found that it seems to be related to a significant improvement in existence. The pain of cancer patients. These effects lasted for almost 5 years after drug administration.
In an original study published in the Journal of Psychopharmacology, psilocybin resulted in immediate, substantial and sustained improvement in anxiety and depression, reducing cancer-related demoralization and despair, improving mental well-being, and improving quality of life. It led to the improvement of. In a follow-up assessment of the last 6.5 months, psilocybin was associated with persistent anxiety and antidepressant effects. Approximately 60-80% of participants continued to have a clinically significant reduction in depression and anxiety, sustained benefits of existential distress and quality of life, and improved attitudes towards death.
The current study, published online January 28 in the same journal, is a long-term follow-up study of a subgroup of participants from the original study, rated approximately 3 years and 4.5 after a single dose of psilocybin. It's the year. .. This study reports a continuous reduction in anxiety, depression, despair, demoralization, and distress at both follow-up points.
Approximately 60-80% of participants met clinically significant antidepressant or anxiety response criteria with a 4.5-year follow-up. The overwhelming number of participants (71-100%) bring positive life changes to the experience of psilocybin supportive care, which is the most personally meaningful and psychologically important experience of their life. I evaluated it as one.
"In addition to the evidence dating back to the 1950s, our findings strongly suggest that silocibin therapy is a promising tool for improving the emotional, psychological, and psychological well-being of life-threatening cancer patients. "I will," said the principal investigator. Parental research. 2016. Stephen Ross, MD, Associate Professor of Psychology at NYU Langone Health. "This approach can lead to a paradigm shift in the psychological and existential care of cancer patients, especially those with end-stage disease."
There is an urgent need for alternative means of treating cancer-related anxiety and depression, Dr. Ross said. According to statistics from various sources, nearly 40% of the world's population is diagnosed with cancer in their lifetime, and one-third of them develop anxiety, depression, and other forms of anxiety. To do. According to experts, these conditions are associated with poor quality of life, increased suicide rates, and decreased survival rates.
Unfortunately, traditional pharmacological treatments, such as antidepressants, are effective in less than half of cancer patients and are usually less effective than placebo. Moreover, they do not affect existential or distress. These are often associated with a diagnosis of cancer and are associated with an accelerated craving for death and an increased suicidal tendency, says Dr. Ross.
Researchers say psilocybin can be a useful tool for improving the effectiveness of psychotherapy and ultimately alleviating these symptoms. The exact mechanism is not fully understood, but experts believe the drug will make the brain more flexible and accept new ideas and thought patterns. In addition, previous studies have shown that the drug targets the brain network, the default mode network. The default mode network is activated when we introspect and wander our thoughts, helping to strengthen our sense of self and a sense of consistent narrative identity. create. In patients with anxiety and depression, this network becomes hyperactive, with rumination, worry, and rigorous thinking. Psilocybin seems to rapidly change the activity of this network and help people gain a broader view of their behavior and life.
How the initial investigation and follow-up was done In the original study, the NYU Langone team had nine psychotherapy sessions in 29 cancer patients and a single dose of psilocybin or active placebo, niacin, which could produce a physical flushing sensation similar to the experience of psychedelic drugs. Provided administration. After 7 weeks, all participants switched treatments and were monitored for clinical outcome measurements such as anxiety, depression, and exi.